Clinical outcomes and prognostic factors of patients with epithelial ovarian cancer subjected to first-line treatment: A retrospective study of 251 cases

Frontiers of Medicine in China

Volumn 8, Issue 1, 2014, Pages 91-95

  Fu, Yunfeng ^a   Wang, Xinyu ^a   Pan, Zimin ^a   Xie, Xing ^a,b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Women's Reproductive Health Laboratory of Zhejiang Province   (China)

Author keywords

chemotherapy; ovarian carcinoma; prognostic factors; surgery; survival

Indexed keywords

CANCER STAGING; FEMALE; HUMAN; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURGERY; SURVIVAL; TREATMENT OUTCOME;

COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84897657101     PISSN: 16737342     EISSN: 16737458     Source Type: Journal    
DOI: 10.1007/s11684-014-0305-7     Document Type: Article

References (9)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62(1): 10-29.
2. Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet 2000; 70(2): 209-262.
3. Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA; National Comprehensive Cancer Network. Ovarian cancer, version 3. 2012. J Natl Compr Canc Netw 2012;10(11): 1339-49.
4. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet 4 Clinical analysis of 251 cases with EOC 2009; 374(9698): 1371-1382.
5. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011; 61(3): 183-203.
6. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002; 360(9332): 505-515.
7. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000; 18(1): 106-115.
8. Husseinzadeh N. Status of tumor markers in epithelial ovarian cancer has there been any progress? A review. Gynecol Oncol 2011; 120(1): 152-157.
9. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20(5): 1248-1259.